Investigation of the Complexes Formed between PARP1 Inhibitors and PARP1 G-Quadruplex at the Gene Promoter Region

被引:4
|
作者
Dallavalle, Sabrina [1 ,2 ]
Princiotto, Salvatore [1 ]
Mattio, Luce M. [1 ]
Artali, Roberto [3 ]
Musso, Loana [1 ]
Avino, Anna [4 ]
Eritja, Ramon [4 ]
Pisano, Claudio [5 ]
Gargallo, Raimundo [6 ]
Mazzini, Stefania [1 ]
机构
[1] Univ Milan, Dept Food Environm & Nutr Sci DEFENS, I-20133 Milan, Italy
[2] Natl Inst Fundamental Studies, Kandy 20000, Sri Lanka
[3] Scientia Advice Roberto Artali, I-20832 Desio, Italy
[4] CSIC, Networking Ctr Bioengn Biomat & Nanomed CIBER BBN, Inst Adv Chem Catalonia IQAC, Barcelona 08034, Spain
[5] Biogem, Res Inst, I-83100 Avellino, Italy
[6] Univ Barcelona, Dept Chem Engn & Analyt Chem, Barcelona 08028, Spain
关键词
NMR spectroscopy; CD; G-quadruplex; molecular modeling; PARP1; inhibitors; fluorescence titration; promoter; dual-targeting; PARTICLE MESH EWALD; MOLECULAR-DYNAMICS; FORCE-FIELD; INTEGRATION; ALGORITHM; BINDING;
D O I
10.3390/ijms22168737
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
DNA repair inhibitors are one of the latest additions to cancer chemotherapy. In general, chemotherapy produces DNA damage but tumoral cells may become resistant if enzymes involved in DNA repair are overexpressed and are able to reverse DNA damage. One of the most successful drugs based on modulating DNA repair are the poly(ADP-ribose) polymerase 1 (PARP1) inhibitors. Several PARP1 inhibitors have been recently developed and approved for clinical treatments. We envisaged that PARP inhibition could be potentiated by simultaneously modulating the expression of PARP 1 and the enzyme activity, by a two-pronged strategy. A noncanonical G-quadruplex-forming sequence within the PARP1 promoter has been recently identified. In this study, we explored the potential binding of clinically approved PARP1 inhibitors to the G-quadruplex structure found at the gene promoter region. The results obtained by NMR, CD, and fluorescence titration confirmed by molecular modeling demonstrated that two out the four PARP1 inhibitors studied are capable of forming defined complexes with the PARP1 G-quadruplex. These results open the possibility of exploring the development of better G-quadruplex binders that, in turn, may also inhibit the enzyme.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Structure of a (3+1) hybrid G-quadruplex in the PARP1 promoter
    Sengar, Anjali
    Vandana, J. Jeya
    Chambers, Vicki S.
    Di Antonio, Marco
    Winnerdy, Fernaldo Richtia
    Balasubramanian, Shankar
    Anh Tuan Phan
    NUCLEIC ACIDS RESEARCH, 2019, 47 (03) : 1564 - 1572
  • [2] Exploring the Interaction of G-quadruplex Binders with a (3+1) Hybrid G-quadruplex Forming Sequence within the PARP1 Gene Promoter Region
    Mazzini, Stefania
    Princiotto, Salvatore
    Artali, Roberto
    Musso, Loana
    Avino, Anna
    Eritja, Ramon
    Gargallo, Raimundo
    Dallavalle, Sabrina
    MOLECULES, 2022, 27 (15):
  • [3] PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs
    Wang, Luyao
    Liang, Chao
    Li, Fangfei
    Guan, Daogang
    Wu, Xiaoqiu
    Fu, Xuekun
    Lu, Aiping
    Zhang, Ge
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (10)
  • [4] Interactions of PARP1 Inhibitors with PARP1-Nucleosome Complexes
    Maluchenko, Natalya
    Koshkina, Darya
    Korovina, Anna
    Studitsky, Vasily
    Feofanov, Alexey
    CELLS, 2022, 11 (21)
  • [5] Selective PARP1 inhibitors, PARP1-based dual-target inhibitors, PROTAC PARP1 degraders, and prodrugs of PARP1 inhibitors for cancer therapy
    Peng, Xiaopeng
    Pan, Wanyi
    Jiang, Feng
    Chen, Weiming
    Qi, Zetao
    Peng, Weijie
    Chen, Jianjun
    PHARMACOLOGICAL RESEARCH, 2022, 186
  • [6] PARP1 expression (PARP1expr) drives synergy between PARP1 inhibitors (PARP1-Is) and trabectedin (TR)
    Pignochino, Ymera
    Capozzi, Federica
    D'ambrosio, Lorenzo
    Dell'aglio, Carmine
    Basirico, Marco
    Boccone, Paola
    Palesandro, Erica
    Gammaitoni, Loretta
    Sangiolo, Dario
    Benassi, Maria Serena
    Aglietta, Massimo
    Grignani, Giovanni
    CANCER RESEARCH, 2016, 76
  • [7] ATR inhibitors and PARP1 selective PARP inhibitors
    Tutt, Andrew
    CANCER RESEARCH, 2023, 83 (05)
  • [8] Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
    Murai, Junko
    Huang, Shar-yin N.
    Das, Benu Brata
    Renaud, Amelie
    Zhang, Yiping
    Doroshow, James H.
    Ji, Jiuping
    Takeda, Shunichi
    Pommier, Yves
    CANCER RESEARCH, 2012, 72 (21) : 5588 - 5599
  • [9] α-Aminophosphonates as Potential PARP1 Inhibitors
    Schweiker, Stephanie S.
    Tauber, Amanda L.
    Kam, Caleb M.
    Eyckens, Daniel J.
    Henderson, Luke C.
    Levonis, Stephan M.
    CHEMISTRYSELECT, 2020, 5 (14): : 4205 - 4209
  • [10] PARP inhibition: PARP1 and beyond
    Rouleau, Michele
    Patel, Anand
    Hendzel, Michael J.
    Kaufmann, Scott H.
    Poirier, Guy G.
    NATURE REVIEWS CANCER, 2010, 10 (04) : 293 - 301